Pfizer Inc. (PFE)
| Market Cap | 151.52B +3.4% |
| Revenue (ttm) | 62.58B -1.6% |
| Net Income | 7.77B -3.2% |
| EPS | 1.36 -3.4% |
| Shares Out | 5.69B |
| PE Ratio | 19.53 |
| Forward PE | 9.00 |
| Dividend | $1.72 (6.45%) |
| Ex-Dividend Date | Jan 23, 2026 |
| Volume | 44,794,718 |
| Open | 26.71 |
| Previous Close | 26.86 |
| Day's Range | 26.36 - 26.78 |
| 52-Week Range | 20.92 - 27.94 |
| Beta | 0.44 |
| Analysts | Hold |
| Price Target | 27.18 (+1.99%) |
| Earnings Date | Feb 3, 2026 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $27.18, which is an increase of 1.99% from the latest price.
News
Is There 25% Downside For Pfizer Stock?
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price ...
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and C...
Pfizer: The Rebound Looks Unsustainable
Pfizer Inc. delivered a 17% total return since early November, but I remain cautious. I do not recommend buying PFE stock, as the recent rally is not supported by fundamentals. Valuation analysis and ...
Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial,...
Prices, pipelines and patent cliffs: Inside pharma's big reset
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Pfizer: A Great Opportunity Post Earnings
Pfizer remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. PFE's non-COVID portfolio posted 6% operational growth in 2025, with international market...
Is Pfizer Stock Now A Value Trap?
Pfizer (PFE) is confronting challenges. Even the most prominent companies are not beyond reach.
Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
Pfizer agreed to accept $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen...
Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity
Pfizer (PFE) remains a 'Hold' due to near-term headwinds, including a $1.5B patent cliff in 2026 and declining Covid-19 revenues. PFE's long-acting GLP-1 obesity program, bolstered by the Metsera acqu...
Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
Pfizer made one thing clear this week: It's officially back in the obesity race.
14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)
February's top Large Cap Value (GASV) stocks offer 27.69% to 69.77% net gains by February 2027, based on analyst targets. Fourteen of twenty-nine 'safer' lowest-priced GASV 'dogs' are currently buyabl...
FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics Li...
Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting t...
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Pfizer: Messy Q4 Earnings Mask An Improving Business
Pfizer Inc. earns a Buy rating as the market overreacts to Q4's non-cash loss and conservative 2026 guidance, overlooking underlying operational strength. Excluding COVID-19 products, PFE posted 9% Yo...
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-...
Silver Surges Over 15%; Pfizer Earnings Top Views
On Tuesday, Pfizer Inc. (NYSE:PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus estimates.
Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever
Pfizer reported Q4 and FY2025 revenues and EPS above expectations, but core revenues declined due to falling COVID product sales. Despite a 6.5% dividend yield and low valuation multiples, PFE remains...
Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways
Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.
Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products.
Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops
On Tuesday, Pfizer Inc. (NYSE: PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus estimates.
Pfizer maps post-Covid reset with obesity trials and deep cost cuts
Pfizer reported fourth-quarter results that beat expectations, offering a steadier earnings picture as the company moves further away from the Covid-driven revenue surge of recent years. While demand ...
Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration's policies on pricing and tariffs.